Combination therapy of BRAF inhibitors for advanced melanoma with BRAF V600 mutation: a systematic review and meta-analysis

S Kim, HT Kim, HS Suh - Journal of Dermatological Treatment, 2018 - Taylor & Francis
… in the meta-analysis, neither had an impact on the results. Finally, although we identified
several regimens combining BRAF … Therefore, all studies that included BRAF inhibitors and …

[HTML][HTML] Efficacy and safety of BRAF inhibition alone versus combined BRAF and MEK inhibition in melanoma: a meta-analysis of randomized controlled trials

M Liu, X Yang, J Liu, B Zhao, W Cai, Y Li, D Hu - Oncotarget, 2017 - ncbi.nlm.nih.gov
… results of our meta-analysis also demonstrated that combined BRAF and MEK inhibition …
BRAF inhibition alone [29]. Given the significantly better survival outcomes, the combined BRAF

[HTML][HTML] … safety of targeted therapies for BRAF-mutant unresectable or metastatic melanoma: Results from a systematic literature review and a network meta-analysis

P Corrie, N Meyer, R Berardi, M Guidoboni… - Cancer Treatment …, 2022 - Elsevier
… Results of the analysis showed that combination therapies generally achieve improved
OS outcomes compared to monotherapies (ie, dabrafenib, vemurafenib and dacarbazine). …

Clinical outcomes of BRAF plus MEK inhibition in melanoma: A metaanalysis and systematic review

Q Yu, J Xie, J Li, Y Lu, L Liao - Cancer Medicine, 2019 - Wiley Online Library
… a meta-analysis to evaluate the efficacy and safety between BRAF inhibition plus MEK inhibition
combination … Our meta-analysis suggests that BRAF inhibition in combination with MEK …

Therapeutic efficacy and safety of combined BRAF and MEK inhibition in patients with malignant melanoma: a meta-analysis

P Chen, F Chen, B Zhou - OncoTargets and therapy, 2017 - Taylor & Francis
… Citation21 Consistent with this, the results of our meta-analysis also demonstrated that
combined BRAF and MEK inhibition provided significant advantage in ORR, PFS, and OS over …

[HTML][HTML] Therapeutic efficacy of combined BRAF and MEK inhibition in metastatic melanoma: a comprehensive network meta-analysis of randomized controlled trials

R Mai, S Zhou, W Zhong, S Rong, Z Cong, Y Li, Q Xie… - Oncotarget, 2015 - ncbi.nlm.nih.gov
meta-analysis indicated the combined BRAF and MEK inhibition will be essential for maximizing
clinical benefit of combining … cell-rich infiltrate during combined BRAF and MEK-targeted …

Network meta-analysis of therapies for previously untreated advanced BRAF-mutated melanoma

MJ Zoratti, T Devji, O Levine, L Thabane… - Cancer Treatment Reviews, 2019 - Elsevier
… for patients with metastatic BRAF-mutated melanoma is broad, … a network meta-analysis
(NMA) in previously untreated, BRAF-… Based on our treatment-level analysis, combination BRAF

[HTML][HTML] BRAF and MEK inhibitors and their toxicities: a meta-analysis

M Garutti, M Bergnach, J Polesel, L Palmero… - Cancers, 2022 - mdpi.com
BRAF metastatic melanoma is based on the combination of … The goal of this meta-analysis
was to provide a useful tool to … the different combinations of BRAF and MEK inhibitors used in …

Prognostic implication of BRAF and TERT promoter mutation combination in papillary thyroid carcinoma—a metaanalysis

HG Vuong, AMA Altibi, UNP Duong… - Clinical …, 2017 - Wiley Online Library
combination of BRAFBRAF and TERT promoter mutations exhibit the most aggressive
clinical course as denoted by this spectrum: BRAF+/TERT+ > TERT+ only=BRAF+ only > BRAF−/…

The risk of dermatological toxicities of combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma patients: a systematic review and meta-analysis

P Chen, F Chen, B Zhou - Cutaneous and Ocular Toxicology, 2019 - Taylor & Francis
… the fact that combined BRAF and MEK … meta-analysis was to appraise the differences in
risk of selected dermatological toxicities of combined BRAF and MEK inhibition versus the BRAF